Organovo Reports Q1 Fiscal 2014 Results, Provides Business Update

SAN DIEGO, Aug. 12, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo") a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has reported on its financial results for the three-month period ended June 30, 2013 and provides a business update.

Recent Corporate Highlights

Presented data on first fully cellular 3D Bioprinted Liver Tissue

Listed common stock on the NYSE MKT

Successfully completed $46.6 million public offering

Appointed Tamar D. Howson to the Company's Board of Directors

Nominated Richard Heyman Ph.D. for election to the Board of Directors at the upcoming Annual Meeting

Changed fiscal year-end from December 31st to March 31st

Organovo and Methuselah Foundation Announced Funding of Bioprinting Research at Research Institutions

On April 26th, Organovo described the first fully cellular 3D bioprinted liver tissue, having presented data on its in vitro three-dimensional liver at the 2013 Experimental Biology conference in Boston, Massachusetts. For the first time, human liver tissues were generated that were truly three-dimensional, being up to 500 microns in thickness in the smallest dimension, and consisting of multiple cell types arranged in defined spatial patterns that reproduce key elements of native tissue architecture and demonstrated excellent functional characteristics that replicates human biology better than what has come before.

On July 9th, Organovo announced that its common stock had been approved for listing on the New York Stock Exchange MKT. Trading commenced on the NYSE MKT on July 11th, and Company's CEO Keith Murphy rang the opening bell at the NYSE on July 15 th.

On August 7 th, Organovo successfully completed a public offering in which it raised gross proceeds of $46.6 million through the issuance of 10,350,000 shares of its common stock.

On June 10th, Organovo announced the appointment of Tamar D. Howson to its Board of Directors. Ms. Howson is a seasoned business development executive within the pharmaceutical industry, having formerly served as senior vice president of both Bristol-Meyers Squibb and SmithKline Beecham. She currently serves as a business development and strategy consultant to biopharmaceutical companies. She also serves as a director at Idenix, Oxigene Pharmaceuticals, and Warner Chilcott.

On July 18th, Organovo announced that Richard A. Heyman, Ph.D. had been nominated to be elected to the Company's Board of Directors at the Annual Meeting of Shareholders scheduled to be held on August 21, 2013. Dr. Heyman is an experienced life science executive who is currently chief executive officer of Aragon Pharmaceuticals, which he co-founded in 2009. In June 2013, Aragon announced a definitive agreement with Johnson and Johnson whereby Aragon will be acquired for up to $1 billion dollars in total transaction value. Previously, Dr. Heyman was Chief Scientific Officer at Kalypsys, Inc.

On April 3rd, Organovo announced a fiscal year-end change from December 31st to March 31st, in alignment with its intention to list its common stock on a U.S. exchange at the earliest available opportunity.

On July 24th, Organovo announced that Methuselah Foundation has initiated a campaign in which it will fund research at major research institutions using Organovo's proprietary NovoGen Bioprinting technology. The program will feature grants of research funding from the non-profit Methuselah Foundation to major academic research centers engaged in cutting-edge biomedical research. Eligible institutions will include public and private research universities and private non-profit research institutes. Under the program, Methuselah Foundation will divide a donation of at least $500,000 in direct funding for research projects across several institutions.

"Organovo has consistently and effectively executed its business plan from both a technology and business perspective," stated Keith Murphy, chief executive officer of Organovo. "Following our recent capital raise, we are well positioned to grow long-term shareholder value through development and launch of our first commercial product in 2014, through the capture of additional collaborative partnerships, and through expanded investment in the development of therapeutic tissues intended for implantation."

Financial ResultsFor the three months ended June 30, 2013, total revenues of approximately $0.1 million were $0.2 million or 67% below the approximately $0.3 million in revenues for the same period in 2012. This decrease reflects the planned phasing of deliverables under the original project scope of our collaborative arrangements despite current overall increases in collaborative research activities. The Company is increasing its internal investment in these collaborative activities with the intention of accelerating the growth of shareholder value.

Operating expenses increased approximately $2.1 million or 124% in the three months ended June 30, 2013 over the same period in 2012, from approximately $1.7 million in 2012 to $3.8 million in 2013. Most significantly, relative to the same period in the prior year, the Company invested in building its research, development and administrative staff, increasing its headcount from 21 full-time employees as of June 30, 2012 to 35 full-time employees as of June 30, 2013, including 24 employees within research and development. Consequently payroll and benefits expenses increased by approximately $0.5 million or 70% over the same period in 2012, and stock-based compensation increased from under $0.1 million to $0.8 million for the same periods. To accommodate our growing research and development needs the Company relocated to a larger space, tripling our facilities related expenses when compared to prior periods. With the increased research and development activity and output, inputs such as lab supplies and contracted services increased across the board. Finally, the Company incurred approximately $0.3 million more in external expenses related to public company status versus the same period, prior year, in addressing SEC financial reporting, investor relations, corporate governance and audit requirements.

The approximate $33.9 million decrease in other expense for the three month period ending June 30, 2013 compared to the same period of the prior year, was primarily related to 2012 non-cash transaction costs associated with the warrants issued in our 2012 Private Placement. Due to the majority of the underlying warrants being exercised prior to June 30, 2013, or modified and reclassified to equity, the net warrant derivative liability was substantially less than in the same period of 2012 due to significantly fewer underlying warrants.

The Company also had negative cash flow from operations of $2.7 million during the three months ended June 30, 2013, with end-of-period cash and cash equivalents of approximately $12.8 million and an accumulated deficit of $70.1 million. At June 30, 2012, the Company had cash and cash equivalents of approximately $8.5 million and an accumulated deficit of $79.2 million. At June 30, 2013, the Company had total current assets of approximately $13.3 million and current liabilities of approximately $7.6 million, resulting in working capital of $5.7 million. At June 30, 2012, we had total current assets of approximately $9.2 million and current liabilities of approximately $0.9 million, resulting in working capital of $8.3 million. Subsequently, on August 7, 2013, the Company sold 10,350,000 shares of the Company's common stock, with net proceeds to the Company of approximately $43.3 million, after deducting underwriting discounts and commissions and estimated offering expenses of $3.3 million.

As of June 30, 2013, the Company had 64,951,014 total issued and outstanding shares of Common Stock, and five year warrants for the opportunity to purchase an additional 3,481,760 shares of Common Stock at exercise prices between $0.85 and $1.00 per share and 550,000 warrants with terms between two and five years and exercise prices between $2.21 and $3.24 per share. Subsequent to June 30, 2013, the Company had 1,242,478 warrants exercised on a cashless basis, for a net issuance of 981,055 shares and 225,000 warrants exercised for 225,000 common shares for cash proceeds to the Company of $609,000. In aggregate, issued and outstanding common stock, shares underlying outstanding warrants, and shares reserved for the 2008 and 2012 incentive plans total 74,267,596 shares of common stock as of June 30, 2013.

About Organovo Holdings, Inc.Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.

Safe Harbor StatementAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology;; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our report on Form 10-Q filed August 9, 2013, the prospectus supplement filed with the SEC on August 2, 2013 and the transition report on Form 10-KT filed with the SEC on May 24, 2013 and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.